IVD

VC Firms Still Find Liquid Biopsy Sexy

A $45 million funding round completed by DiaCarta to help develop a liquid biopsy test for colorectal cancer is just the latest proof that venture capitalists continue to see liquid biopsy companies as an attractive investment.